To determine whether somatically mutated ABL1/2 may be required to maintain lung cancer cell survival, we treated this panel of NSCLC cancer cell lines harboring mutations in either ABL1 or ABL2 (H1915, H2110, H650, and H1623), with ABL inhibitors, and monitored cell viability. This evidence concerns the gene ABL1 and cancer.